Drug Details
| General Information of the Drug (ID: DR7340) | ||||
|---|---|---|---|---|
| Name |
Brentuximab vedotin
|
|||
| Molecular Type |
Antibody
|
|||
| Disease | Hodgkin lymphoma [ICD-11: 2B30] | Approved | [1] | |
| ADMET Property |
Elimination
About 24% of the total MMAE ingested as part of the ADC during an ADCETRIS infusion was recovered in both urine and feces over a 7-day time frame
Half-life
The concentration or amount of drug in body reduced by one-half in 4 - 6 days
Metabolism
The drug is metabolized via oxidation by CYP3A4/5
Click to Show/Hide
|
|||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Vinblastine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Experimental
Result(s) |
The results of the ECHELON-1 study showed a significantly longer modified progression-free survival (mPFS) following BV+AVD than with ABVD in primary HL. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Lymphocyte activation antigen CD30 (TNFRSF8) | Molecule Info | [3] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | Click to Show/Hide | ||
| NetPath Pathway | Leptin Signaling Pathway | Click to Show/Hide | ||
| 2 | TCR Signaling Pathway | |||
